FDA Cleared Expansion Advin Biotech holds FDA registered status and 501k cleared rapid diagnostics products, indicating a credible platform for expanding into additional drug-of-abuse testing menus for both workplace and criminal justice markets.

OEM and Co-Development With in-house R&D and immunogen/antibody design capabilities, there is a clear opportunity to partner on co-development for first-to-market, organics-grown assays that address unmet needs in toxicology testing.

US and China Ops Dual manufacturing presence in San Diego and China enables flexible supply chains and potential near-shoring or regionalized production partnerships to support global customers and reduce lead times.

Funding Momentum Recent $4.5M funding award signals investor confidence and potential for growth, opening doors for co-investment, strategic alliances, and faster scale for new assay lines.

Market Positioning Current focus on workplace and criminal justice drug-of-abuse tests positions Advin to target large, regulated markets; collaboration with like-minded distributors and testing networks could accelerate market penetration.